MX9805284A - Mutantes de riboflavina como vacunas contra actinobacillus pleuropneumoniae. - Google Patents

Mutantes de riboflavina como vacunas contra actinobacillus pleuropneumoniae.

Info

Publication number
MX9805284A
MX9805284A MX9805284A MX9805284A MX9805284A MX 9805284 A MX9805284 A MX 9805284A MX 9805284 A MX9805284 A MX 9805284A MX 9805284 A MX9805284 A MX 9805284A MX 9805284 A MX9805284 A MX 9805284A
Authority
MX
Mexico
Prior art keywords
riboflavin
mutants
actinobacillus pleuropneumoniae
vaccines against
against actinobacillus
Prior art date
Application number
MX9805284A
Other languages
English (en)
Inventor
Martha H Mulks
Troy E Fuller
Brad J Thacker
Original Assignee
Univ Michigan State
Univ Iowa State Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan State, Univ Iowa State Res Found Inc filed Critical Univ Michigan State
Publication of MX9805284A publication Critical patent/MX9805284A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a una vacuna contra el Actinobacillus pleuropneumoniae (APP), que comprende un mutante atenuado bioquímicamente, definido genéticamente, del APP, que requiere rivoflavina, y que es atenuado in vivo.
MX9805284A 1996-10-28 1998-06-29 Mutantes de riboflavina como vacunas contra actinobacillus pleuropneumoniae. MX9805284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/741,327 US5925354A (en) 1995-11-30 1996-10-28 Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae

Publications (1)

Publication Number Publication Date
MX9805284A true MX9805284A (es) 1998-10-31

Family

ID=24980274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805284A MX9805284A (es) 1996-10-28 1998-06-29 Mutantes de riboflavina como vacunas contra actinobacillus pleuropneumoniae.

Country Status (10)

Country Link
US (2) US5925354A (es)
EP (1) EP0948616A2 (es)
JP (1) JPH11504662A (es)
AR (1) AR009599A1 (es)
AU (1) AU5155098A (es)
CA (1) CA2241626A1 (es)
MX (1) MX9805284A (es)
NO (1) NO982995D0 (es)
WO (1) WO1998018917A2 (es)
ZA (1) ZA979657B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US6335424B1 (en) * 1996-08-16 2002-01-01 Smithkline Beecham Corporation ribG
US6682891B2 (en) 1997-08-15 2004-01-27 E. I. Du Pont De Nemours And Company Methods of identifying nucleic acid sequences encoding plant riboflavin synthase enzymes
US6277651B1 (en) * 1998-07-09 2001-08-21 Calspan Srl Corporation Diode laser electrochemical sensor for detecting chemical and biological analytes
DE19910102B4 (de) * 1999-03-08 2006-06-01 Fischer, Markus, Dr.rer.nat. Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben
KR20060116041A (ko) * 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
EP1372721A4 (en) * 2001-03-07 2008-04-02 Childrens Medical Center METHOD FOR SCREENING PEPTIDE DISPLAY LIBRARIES WITH A MINIMUM DISPLAY
US9701737B2 (en) * 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
US20120077781A1 (en) * 2008-08-11 2012-03-29 Robert Gadwood Flavin derivatives
SI3564357T1 (sl) 2010-02-01 2022-09-30 Rebiotix, Inc. Bakterioterapija Clostridium Difficile colitisa
US20130129695A1 (en) * 2010-02-04 2013-05-23 Kenneth Blount Methods for treating or inhibiting infection by clostridium difficile
AU2013304048B2 (en) * 2012-08-17 2018-03-01 Intervet International B.V. An immunogenic composition of killed Leptospira bacteria
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102093537B1 (ko) 2013-06-05 2020-04-23 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt), 조성물 및 제조방법
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
CN104496992B (zh) * 2014-12-29 2016-06-29 中国人民解放军国防科学技术大学 用于蓝光受体光致电子转移研究的模型化合物及其制备方法
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
BR112017026586B1 (pt) 2015-06-09 2021-11-03 Rebiotix, Inc. Composições de terapia de restauração de microbiota (mrt) e métodos de fabricação
WO2024096123A1 (ja) * 2022-11-04 2024-05-10 株式会社バイオパレット 遺伝子が改変された微生物およびその生産方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK138379A (da) * 1979-04-04 1980-10-05 Nordisk Droge & Kemikalie Vaccine imod pleuropneumonia (ondartet lungesyge) hos svin dens anvendelse samt fremgangsmaade og substat til dyrkning specielt aerob fermentering af mikroorganismen haemophilus pleuropneumoniae
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US5120655A (en) * 1985-12-20 1992-06-09 Zeagen, Inc. Riboflavin producing strains of microorganisms
US5468485A (en) * 1987-06-04 1995-11-21 Washington University Avirulent microbes and uses therefor
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
NL8802007A (nl) 1988-08-12 1990-03-01 Centraal Diergeneeskundig Inst Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins.
US5332572A (en) * 1988-11-10 1994-07-26 Iowa State University Research Foundation Method for protection of swine against pleuropneumonia
DK0465560T3 (da) * 1989-03-31 1996-10-28 Univ Washington Vacciner indeholdende avirulente mikroorganismer af phoP-type
CN1066486C (zh) * 1989-06-22 2001-05-30 霍夫曼-拉罗奇有限公司 高产核黄素的细菌菌株
US5837528A (en) * 1989-06-22 1998-11-17 Hoffmann La Roche, Inc. Bacterial strains which overproduce riboflavin
FR2652266B1 (fr) * 1989-09-26 1994-08-12 Rhone Merieux Vaccin protecteur contre l'hemophilose porcine.
US5641653A (en) * 1989-10-31 1997-06-24 The Texas A&M University System DNA encoding Actinobacillus pleuropneumoniae hemolysin
EP0453024B1 (en) 1990-04-20 1995-05-31 Akzo Nobel N.V. Actinobacillus pleuropneumoniae subunit vaccine
CA2045950C (en) * 1991-06-28 2004-05-11 Elbarte M. Kamp Recombinant vaccine for prevention and/or treatment of pleuropneumonia infections
WO1993010815A1 (en) * 1991-12-06 1993-06-10 Center For Innovated Technology Non-capsulated mutants of bacteria useful as vaccines
WO1993021951A1 (en) * 1992-04-27 1993-11-11 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US6656477B1 (en) * 1992-07-28 2003-12-02 Board Of Trustees Of Michigan State University 43 Kd protein vaccine and method for the production thereof
JP2634545B2 (ja) 1992-10-27 1997-07-30 日本全薬工業株式会社 Ｒｔｘトキシンファミリーに属する細菌毒素ワクチンの製造法
WO1994009821A1 (en) * 1992-11-05 1994-05-11 Cornell Research Foundation, Inc. Recombinant vaccine for porcine pleuropneumoniae
US5456914A (en) * 1993-01-26 1995-10-10 Board Of Regents Of The University Of Nebraska Transthoracic intrapulmonary immunization against Actinobacillus pleuropneumoniae
US5389386A (en) 1994-06-30 1995-02-14 Church & Dwight Co., Inc. Method of controlling fungal disease in cultivated plants
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae

Also Published As

Publication number Publication date
NO982995D0 (no) 1998-06-26
WO1998018917A3 (en) 1998-08-13
EP0948616A2 (en) 1999-10-13
ZA979657B (en) 1998-08-19
CA2241626A1 (en) 1998-05-07
US6410021B1 (en) 2002-06-25
AU5155098A (en) 1998-05-22
AR009599A1 (es) 2000-04-26
JPH11504662A (ja) 1999-04-27
WO1998018917A2 (en) 1998-05-07
US5925354A (en) 1999-07-20

Similar Documents

Publication Publication Date Title
MX9805284A (es) Mutantes de riboflavina como vacunas contra actinobacillus pleuropneumoniae.
EP0555366A4 (en) Bacterial attenuation method and vaccine
HU9600371D0 (en) Pharmaceutical formulations of nerve growth factor
EP0762892A4 (en) DIPHTERIC ANTI-TOXIN VACCINES CARRYING A R mutating domain
AU6875398A (en) Methods of producing and using virulence attenuated (poxr) mutant bacteria
AU4269893A (en) Jacks and dentist's or other chairs
EP1024827A4 (en) COMPOSITIONS AND METHODS FOR THE SYSTEMIC ADMINISTRATION OF ORAL VACCINALS AND THERAPEUTIC ACTIVE SUBSTANCES
AU6118096A (en) Immunogenic and immunostimulatory oligosaccharide compositio ns and methods of making and using them
SG139553A1 (en) 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof
AU7780391A (en) Low level blasting composition and method of blasting same
IL121585A0 (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods of preparing and using them
PL333127A1 (en) Acellualr pertussis vaccine with diphteria and tetanus anatoxin
AU3737789A (en) Method and compositions for treatment of parkinsonism syndrome in mammals
HU9202095D0 (en) Therapy and vaccine against aids
AU8404891A (en) Flavor delivery system with improved release and method of preparation
AU2273497A (en) Vaccine for b-cell malignancies
HU9203481D0 (en) Cyclic and linear peptones having medical effect
EP0488583A3 (en) Improved kit and method for administration of bacillus calmette-guerin
AU7724191A (en) Method for reducing unsaturation of polyethers and low unsaturation polyethers so obtained
AU5565890A (en) An acaricidal composition and use thereof in disinfesting treatments
AU2246188A (en) Stable genomic integration and expression of foreign coding sequences in yeast
ZA964107B (en) Enzyme degrading rhamnogalacturonane ii methods for obtaining said enzyme and rhamnogalacturonane ii and use of said enzyme
IL84258A (en) Preparation of a mutant strain of bordetella bronchiseptica and live attenuated vaccine produced therefrom
GB9010359D0 (en) Enzyme and its preparation
AU3565289A (en) Immunogenic complex and its use in vaccination